Introduction: Polycystic ovary syndrome (PCOS) is a frequent endocrinopathy in young women with significantly increased cardiometabolic risk. Siblings of women with this disorder are at increased risk of insulin resistance and androgen excess. The current study was aimed at investigating cardiometabolic effects of atorvastatin in sisters of women with PCOS.
Methods: This prospective observational study compared two age-, body mass index-, blood pressure-, and plasma lipid-matched groups of women with hypercholesterolemia: sisters of PCOS probands (group A) and unrelated control subjects (group B), receiving atorvastatin (40 mg daily). Plasma lipids, glucose homeostasis markers, concentrations of sex hormones, high-sensitivity C-reactive protein (hsCRP), homocysteine, fibrinogen and uric acid, and the urinary albumin-to-creatinine ratio (UACR) were measured before entering the study and 6 months later.
Results: Both groups differed in the degree of insulin resistance, testosterone, free androgen index (FAI), circulating levels of hsCRP and homocysteine, and UACR. There were no between-group differences in the impact of atorvastatin on plasma lipids. Despite reducing hsCRP and homocysteine in both groups of women, the effect on these biomarkers was stronger in group B than in group A. Only in group B, atorvastatin did reduce fibrinogen, uric acid, and UACR. Only in group A, atorvastatin did worsen insulin sensitivity and tended to reduce testosterone and FAI. The impact of atorvastatin on hsCRP, homocysteine, fibrinogen, uric acid, and UACR inversely correlated with testosterone and FAI.
Conclusion: The obtained results suggest that sisters of women with PCOS may benefit to a lesser degree from atorvastatin treatment than other women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000531321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipoprotein(a), high-sensitivity c-reactive protein, homocysteine and cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis.
Am J Prev Cardiol
March 2025
Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Background And Aims: Elevated lipoprotein(a) [Lp(a)], high-sensitivity C-Reactive Protein (hs-CRP), and total homocysteine (tHcy) are associated with atherosclerotic cardiovascular disease (ASCVD) risk. This study investigated the individual and joint associations of Lp(a), hs-CRP and tHcy with coronary heart disease (CHD) and stroke.
Methods: This study was conducted in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (2000-2017) (CHD analytic = 6,676; stroke analytic = 6,674 men and women).
Prediction Models for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis.
Public Health Nurs
January 2025
School of Nursing, Evidence-Based Nursing Center, Lanzhou University, Lanzhou, China.
Background: Stroke is one of the most serious illnesses worldwide and is the primary cause of acquired disability among adults. Post-stroke cognitive impairment (PSCI) is a complication of stroke that significantly impacts patients' daily activities and social functions. Therefore, developing a risk prediction model for PSCI is essential for identifying and preventing disease progression.
View Article and Find Full Text PDFEffect of plasma homocysteine on cardiometabolic multimorbidity among Chinese adults: a population-based and real-world evidence study.
Front Nutr
December 2024
Clinical Epidemiology Research Office, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
Aims: To explore the effect of plasma homocysteine (Hcy) on cardiometabolic multimorbidity (CMM) among Chinses adults.
Methods: This study combined a community-based cross-sectional study with a 1:1 matched case-control study using propensity score method among adults aged over 30 years in six districts randomly selected from Hunan Province, China. We recruited 5,258 people, of whom 4,012 met the study criteria were enrolled.
A Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.
Cureus
December 2024
Public Health Sciences, Scientific Knowledge for Ageing and Neurological Ailments (SKAN) Research Trust, Bengaluru, IND.
Article Synopsis
- Cardiovascular disease (CVD) is a major global health issue, making it essential to find biomarkers that can detect it early in healthy people to enhance preventive measures and improve overall health outcomes.
- Various biomarkers, such as atherogenic lipoproteins and inflammatory markers like C-reactive protein (CRP), have shown connections to CVD risk factors, aiding in risk prediction when combined with traditional indicators.
- Emerging biomarkers like myeloperoxidase (MPO) and procalcitonin (PCT) are being explored for their potential in early detection of systemic infections, emphasizing the importance of identifying the best biomarker combinations for effective diagnosis and risk assessment.
Evaluation of serum galectin-3 concentration as a potential biomarker in exudative-type age-related macular degeneration.
Sci Rep
December 2024
Department of Ophthalmology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, 53100, Turkey.
To investigate the effect of serum galectin-3 on naive neovascular AMD and its use as a serum marker by revealing the variation in this molecule between patient and control groups. Fifty-six naive neovascular AMD patients and 30 healthy control age-matched healthy subjects were included in this prospective case‒control study. Blood samples were obtained and used for analysis of complete blood count; High sensitivity C-reactive protein (HsCRP), erythrocyte sedimentation rate (ESR), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), total cholesterol, homocysteine, HbA1c and galectin-3 levels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!